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EXPANSION OF COMMMON MYELOID PROGENITORS IN CHRONIC MY-
ELOMONOCYTIC LEUKEMIA
Jamieson, C.H.M.1,2, Li, K.2, Weissman, I.L.2 1. Division of Hema-
tology, Stanford, CA; 2. Department of Pathology, Stanford, CA
Chronic myelomonocytic leukemia (CMML) is a unique myelo-
proliferative disease characterized by marrow dysplasia and an
increase in monocytes. The median survival of patients with
CMML is short (approximately 2 years), in part, because CMML
is frequently resistant to therapy including allogeneic peripheral
blood progenitor transplantation. In order to reduce regimen re-
lated toxicity and provide more effective CMML targeted thera-
pies, a better understanding of the basic biology of CMML pro-
genitors is required. We used FACS analysis and recently
identiﬁed phenotypic markers to identify phenotypic and func-
tional differences between normal and CMML bone marrow he-
matopoietic stem cells and myeloid progenitors. CMML marrow
was typiﬁed by a reduction in CD34CD38-CD90Lin-hemato-
poietic stem cells and an expansion of CD34CD38-CD90-
Flk2Lin-cells relative to normal bone marrow. In addition, there
was a two-fold expansion in common myeloid progenitors (CMPs)
and a corresponding decrease in megakaryocyte-erythroid progen-
itors (MEPs) suggesting that there was a skew in differentiation
toward the myeloid lineage. In contrast to normal bone marrow
derived CMPs, CMML CMPs gave rise to myeloid but not ery-
throid colonies. Moreover, real time quantitative RT-PCR analysis
of highly puriﬁed FACS-sorted CMML CMPs demonstrated an
increase in expression of two key regulators of myelomonocytic
differentiation, PU.1 and c-jun, compared with normal bone mar-
row. A more detailed understanding of the basic biology of CMML
myeloid progenitors and the genes that work in concert to expand
them may aid in identifying novel molecular targets for CMML
therapy.
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3-DIMENSIONAL MULTI-MODALITY NON-INVASIVE IMAGING OF THE
BONE MARROW ENGRAFTMENT MODEL
Doubrovin, M.1, Mayer-Kuckuk, P.2, Budak-Alpdogan, T.1, Bidaut,
L.1, Cai, S.1, Ponomarev, V.1, Blasberg, R.1, van den Brink, M.1,
Bertino, J.2, Benarjee, D.2, Gelovani, J.3 1. Memorial Sloan-Kettering
Cancer Center, New York, NY; 2. UMDNJ, New Brunswick, NJ; 3.
MD Anderson Cancer Cnter, Houston, TX
The studies of the stem cell biology and engraftment often have
to address the question of the cell homing, migration and local-
ization. We tested feasibility of applying a multi-modality imaging
approach for a non-invasive localization of a genetically modiﬁed
graft. The bone marrow cells of C57BL/6 mice were transduced
using retrovirus bearing hsv-tk/egfp/luc reporter fusion gene, char-
acterized by the GFP expression and the whole bone marrow graft,
including up to 38% GFP-positive cells was transfused to the
lethally irradiated B6.SJL-Ptprc mice. The preliminary informa-
tion on the engraftment and location of the cells over a 4 week
period from the transplant was obtained by bio-luminescent im-
aging (BLI) continuously and the 3-dimentinally resolved data on
the bone-marrow homing were obtained by a combination of
MicroCT and MicroPET using [18F]FEAU as a radiotracer. The
data were conﬁrmed morphologically by GFP microscopy of the
tissue sections. It was also possible to obtain ex vivo biolumines-
cence from the excised organs and tissues incubated with D-
luciferin in vitro. 3-Dimensional reconstruction and processing of
MicroPET and MicroCT images allowed for coregistration of the
major foci of bone marrow transplanted cells within the bone
marrow homing areas. The primary sites of the transplanted cell
targeting were in the epiphyses of the ling bones, spongeous parts
of the skull bones and vertebrae. This analysis allowed differenti-
ating the speciﬁc signal originating from the lumar spine from a
non-speciﬁc radiotracer cleared through the gut. There was a
transient signal noted in the projection of spleen over the second
week post-transplant observed by the BLI. MicroPET images on
days 6 and tissue sample analysis conﬁrmed this ﬁnding. Slightly
decreased radiotracer accumulation discordant to the continuously
increasing BLI signal over the time of observation may denote
speciﬁc changes in susceptibility of the bone marrow cells towards
nucleoside-based radiotracer imaging. MicroCT without contrast
agent appeared to be poorly applicable for soft-tissue imaging, but
crucial for the bone locations. The study proved feasibility of
multi-modality approach for obtaining the information on the
bone-marrow cell localization to speciﬁc organs non-invasively in
live recipients over time combining sensitivity and structural spec-
iﬁcity of different methods. Multiple imaging sessions with intra-
venous administration of the probes were well tolerated by the
animals.
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BOTH TISSUE DERIVED AND BONE MARROW DERIVED STROMAL
CELLS ARE IMMUNOREGULATORY
Kleiner, G.I., Gandia, C., Yu, H., Defaria, W., Santiago, S., Tzakis, A.
University of Miami School of Medicine, Miami, FL
Bone marrow derived mesenchymal stem cells have been dem-
onstrated to have immunosuppressive effects in mice and humans.
These ﬁnding suggest that they may be exploited in organ trans-
plantation settings. Here, we investigated immunoregulatory as-
pects of rat intestinal derived and BM MSCs. Bone marrow was
extracted from six to eight week old DA rats and plated in DMEM
containing 10% Fetal Bovine Serum, 2% L-Glutamine, 1% Pen-
icillin-Streptomycin, and 1% Sodium Pyruvate (Gibco). Every 48
hours, non-adherent cells are discarded. The immunosuppressive
effects of these cells in a allogenic mixed lymphocyte reaction were
investigated. Intestinal derived mesenchymal cells were obtained
by enzymatic (collagenase, dispase) digestion followed by plastic
adherence. Mesenteric lymph nodes from both DA and Lewis rats
were extracted and passed through a metal ﬁlter to extract lym-
phocytes. Irradiated DA lymphocytes were used as stimulators.
Lymphocytes were cultured in IMDM Media containing 1% glu-
tamine, 1% Rat Serum, 1% Non-Essential Amino Acids, 0.1%
Beta-Mercapthanol, 1% Penicillin-Streptomycin, 1% Sodium
Pyruvate, 1% HEPES, and 1% vitamin (Gibco). DA MSCs were
added at gradual concentrations of 105, 104, 103, 102, and 101. After
a four day incubation, 1uCi of tritiated thymidine was added.
Lymphocytes were also cultured with 2 mcg/ml ConA. In MLR
cultures, MSC dramatically suppressed MLR responses (99%)
when added at concentration of 105 MSCs. Suppression was dose
dependent. In ConA cultures, MSC suppression of lymphoid cells
was maximal at 105 cells. MSC suppression was not MHC re-
stricted as Lewis derived MSCs also suppressed MLR and ConA
responses (90%). Intestinal MSCs also suppressed MLR re-
sponses (85%). MSCs suppressed skin graft rejection in an in-
vivo model. The results suggest that BM and tissue derived MSCs
may have clinical utility in transplantation settings.
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COMMON LYMPHOID PROGENITORS REQUIRE COMMON GAMMA (C)
AND C-KIT SIGNALS FOR SURVIVAL IN VIVO
Dudl, E.1, Toyama, A.1, Arber, C.2, BitMansour, A.2, Brown, J.1,
Chung, B.1, Price, M.1, Brown, J.M.Y.2, Weinberg, K.I.1 1. Research
Immunology/ Bone Marrow Transplantation, Childrens Hospital Los
Angeles, Los Angeles, CA; 2. Bone Marrow Transplantation and Infec-
tious Diseases, Stanford University, Stanford, CA
CLP are rare, highly proliferative bone marrow cells which are
committed to T, B, and NK cell maturation, but lack myeloid or
erythroid potential. CLP are phenotypically identiﬁed in marrow
as IL-7R() Lin(-) Sca-1(lo) C-kit(lo) cells. Co-transplantation of
small numbers of CLP in hematopoietic stem cell transplant re-
cipients results in rapid improvements in antigen-speciﬁc immune
function without causing graft-versus-host disease. The mecha-
nisms of CLP survival, proliferation, and development in vivo are
not well understood. Because the IL-7 and c-kit receptors are
simultaneously expressed on CLP, genetic models were used to
determine the role of these two receptor pathways in the mainte-
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nance of CLP in vivo. The IL-7R is comprised of the IL-7R and c
chains. Besides the IL-7R, the c is a component of the receptors
for IL-2, IL-4, IL-9, IL-15, and IL-21. Mice which lack the IL-7R
or c have profound defects in thymopoiesis and are lymphopenic.
C-kit loss-of-function mutants have modest decreases (50%) in
thymic cellularity. Mice doubly mutated for the W41 mutation of
the c-kit catalytic domain, and either null mutations of IL-7,
IL-7R, or c have synergistic blocks in thymopoiesis, and signiﬁ-
cantly decreased numbers of B lymphocytes, consistent with an
effect on CLP. In order to determine the receptors regulating the
CLP pool, the quantity of phenotypic CLP were measured in
C57BL/6J mice with mutations in IL-7, c, c-kit, and a combina-
tion of c-/-KitW41/W41. Control C57BL/6J (B6) mice have approx-
imately 10,500  3,280 CLP per femur. There was a 1.5-2-fold
reduction in CLP frequency for singly mutated strains (7,740 
3,750 in IL-7-/-, 5,040  3,730 in c-/-, 6,530  959 in KitW41/W41,
p  .05 vs B6). c-/-/KitW41/W41 showed an approximately fourfold
decrease, with 2,320  1,070 CLP per femur (P  .05 vs. all other
strains). The decreased CLP in IL-7-/- mice was not as profound as
in the c-/- mice (p  .05 for IL-7-/- vs c-/-), suggesting that either
another c ligand, or another receptor (e.g. c-kit), partially com-
pensates for the lack of IL-7. The decline in CLP numbers was not
due to a global decrease in lymphohematopoiesis, as the number of
marrow cells did not differ signiﬁcantly between strains. The
identiﬁcation of the c-kit and IL-7R as important in survival and
maintenance of CLP is a critical step for the development of strategies
for expansion of lymphoid progenitors for transplantation.
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TRANSIENT HUMAN MEGAKARYOPOIESIS AND PLATELET PRODUC-
TION FOLLOWING UMBILICAL CORD BLOOD TRANSPLANTATION INTO
NOD/SCID MICE
Cogle, C.R., Wainman, D.A., Rimsza, L.S., Sola, M.C., Scott, E.W.,
Slayton, W.B. University of Florida, Gainesville, FL
Umbilical cord blood (UCB) provides a readily available and
effective source of hematopoietic stem cells for the treatment of
malignancies, marrow failure syndromes, and metabolic disorders.
However, prolonged thrombocytopenia is a major complication
after UCB transplantation. In vivo animal models characterizing
human megakaryocyte engraftment after UCB transplantation
have been lacking. Chimeric mice were generated by sublethally
irradiating recipient non-obese diabetic severe combined immuno-
deﬁcient (NOD/scid) mice followed by intravenous injection of
human CD34 cells greatly enriched for hematopoietic stem cells
(HSC)/hematopoietic progenitor cells (HPC) from UCB. A min-
imum of 5 animals was transplanted per time point. At four to six
weeks after xenotransplantation, approximately 60% of NOD/scid
mice had human hematopoietic reconstitution in peripheral blood,
and 90% were chimeric in bone marrow. Additionally, examination
of murine bone marrow and peripheral blood after transplantation
demonstrated human megakaryocyte engraftment and platelet pro-
duction. More speciﬁcally, our results are consistent with a prior
report describing transient human platelet production following
adult PBSC transplantation. Peak peripheral blood platelet pro-
duction occurred at 6 weeks post-transplant with up to 0.63%
human platelet chimerism. To determine the cause of this transient
platelet production UCB grafts were analyzed for contaminating
platelets and found to have none. Moreover, assay of mouse spleens
demonstrated no human platelet sequestration. Secondary trans-
plantation studies are ongoing to determine if engraftment is from
HPC or HSC activity. To explore UCB-derived megakaryocyte
proliferation and differentiation, we used direct immunostaining
and found robust, albeit transient megakaryocyte chimerism in
NOD/scid mouse bone marrow, also peaking at 6 weeks. Further-
more, immunohistochemistry studies demonstrate some of these
UCB-derived megakaryocytes as small and often lacking podocytes
–morphologic characteristics of immaturity. This report estab-
lishes the NOD/scid mouse xenotransplant model to study human
megakaryopoiesis and platelet production after UCB transplanta-
tion. Given the clinical signiﬁcance of delayed platelet engraftment
after UCB transplantation, this preclinical mouse model provides a
system to further assay the molecular mechanism of UCB-derived
megakaryocyte engraftment, development, and platelet release.
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HUMAN BONE MARROW-DERIVED CD133 CELLS CAN BE EX-
PANDED EX-VIVO IN THE PRESENCE OF A POLYAMINE COPPER
CHELATOR
Grynspan, F.1, Landau, E.1, Marikovsky, M.1, Yudin, D.1, Nagler, A.2,
Hasson, A.1, Bulvik, S.3 1. Gamida-Cell Ltd., Jerusalem, Israel; 2.
Hematology, Cord Blood Bank, Chaim Sheba Medical Center, Tel Aviv
University, Tel Hashomer, Tel-aviv, Israel; 3. Hematology Department,
Laniado Hospital, Netanya, Israel
The capacity of the polyamine copper chelator tetraethylenepen-
tamine (TEPA) to induce a marked expansion of human cord
blood-derived CD34 cells was previously demonstrated (Peled
T. et al 2002, Br. J. of Haematology 116:655-661). To examine the
effect of TEPA also on the ex-vivo expansion of bone marrow
(BM)-derived stem cells, we have isolated AC133 cells from fresh
human BM at purities greater than 90% as measured by FACS.
Cell cultures (1104/ml) were expanded in Teﬂon bags, in the
presence of IL-6, TPO, Flt3 ligand and SCF with or without
TEPA (5 uM) for 3 weeks and further incubated with cytokines
only. Cell types were analyzed by FACS. Total mononuclear cell
(TMC) expansion was 1216  176-fold after 5 weeks in TEPA-
treated cultures, representing a 2.5- fold higher expansion level as
compared to a cytokines-treated control population. 3-weeks old
cultures displayed similar amounts of CD34 and AC133 cells,
irrelevant of treatment. However, following 5 weeks of ex-vivo
expansion, TEPA-treated cultures exhibited a signiﬁcant increase
(16.5–fold) in AC133 cells and in CD34 cells (105–fold) expan-
sion, as compared to a cytokines-treated control population. In
addition, CFU following 5 weeks ex-vivo expansion was 21.4
higher in TEPA-treated cultures, as compared to a cytokines-
treated control population. Signiﬁcantly, the number of AC133/
CD38- cells following 3 weeks ex-vivo expansion was 26-fold, as
compared to a cytokines-treated control population. The data
presented here strengthen the usefulness of copper chelators to
induce proliferation of early progenitors that inﬂuence the
long term survival and proliferation of early subset popula-
tions which are especially reduced in bone marrow as compared
to cord blood. The potential of TEPA for increased ex-vivo
expansion of long term capacity stem cells derived from sources
other than cord blood can provide stem cell-based therapies plat-
form for the autologous treatment of vascular, cardiovascular,
diabetes, hepatic, neurodegenerative, skeletal, and other clinical
indications.
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UMBILICAL CORD BLOOD CELLS ENGRAFT AND DIFFERENTIATE IN
CARDIAC TISSUES AFTER HUMAN TRANPLANTATION
Crapnell, K.B., Turner, K., Hall, J., Staba, S., Kurtzberg, J. Duke
University Medical Center, Durham, NC
Introduction: Umbilical cord blood (UCB) stem cells can suc-
cessfully rescue the blood and immune system after myeloblative
transplantation. Preclinical studies have shown that hematopoietic
cells from bone marrow and umbilical cord blood have the ability
to “transdifferentiate” into tissue other then those speciﬁed by
their origin. We asked whether hematopoietic stem cells from
UCB have the ability to differentiate into cardiac muscle in trans-
planted patients with pre-existing cardiac pathology. Methods: An
unfortunate child with Sanﬁlippo Syndrome Type B (Mucopo-
lysaccharide (MPS) III) transplanted with a sex mismatched unre-
lated UCB unit at 4 years of age, engrafted but died 5 months
post-transplant of respiratory failure due to an adenoviral infec-
tion. With parental consent, his heart was studied in order to
determine whether donor derived cells had engrafted and/or dif-
ferentiated at the time of his death. At autopsy heart tissue was
ﬁxed in formalin, embedded in parafﬁn, and stored for future
evaluation. Approximately 2 months later, cardiac tissue was cut
into 5 micron thick sections, dehydrated, and stained with anti-
bodies (Troponin I-C and myosin heavy chain) against cardiac
speciﬁc antigens. These same heart sections were then counter-
stained with FISH for XY chromosomes to differentiate donor and
host cells. Results: We found extensive distribution of female
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